Public Health: Commission Proposes a Progressive Roll-out of the New In Vitro Diagnostic Medical Devices Regulation

The official European Commission press release IP/21/5209 details a crucial regulatory proposal introduced in October 2021 regarding the progressive implementation of the EU In Vitro Diagnostic Medical Devices Regulation (Regulation (EU) 2017/746). Designed to maintain continuous patient care and healthcare system supply chains while preventing shortages of essential medical diagnostic tests—such as COVID-19 kits, HIV detection, blood group testing, and cancer diagnostics—this policy measure extended transition periods for legacy devices already on the market without altering core health or safety standards. The document outlines operational measures to address certified notified body capacity constraints across member states, prioritizing high-risk diagnostic technologies while giving manufacturers and health institutions additional time to transition to rigorous conformity assessment protocols. As an open educational resource, this document serves as a vital primary policy artifact for students, researchers, healthcare managers, legal scholars, and biomedical engineering professionals examining public health administration, EU regulatory frameworks, medical technology governance, and emergency health infrastructure supply chain management.